DaVita (DVA) moved back into focus after reporting first quarter 2026 results that exceeded expectations, lifting its earnings outlook and highlighting progress in its value-based Integrated Kidney Care platform expansion.

DaVita’s recent earnings beat and Integrated Kidney Care expansion come after a strong run, with the 90 day share price return of 35.90% and 1 year total shareholder return of 51.78% pointing to building momentum around the current US$213.04 share price and a reinforced narrative on execution and risk.

If DaVita’s recent move has you thinking about other healthcare opportunities, this could be a useful moment to scan a curated set of 38 healthcare AI stocks

With DaVita now trading around US$213.04 after a sharp 90 day move, the key question is whether the stock still offers value at this level or if the market is already pricing in much of its future growth potential?

Most Popular Narrative: 10% Overvalued

DaVita's most followed narrative pegs fair value at about $193.71 per share, which sits below the recent $213.04 price and frames the latest rally against a more cautious long term model built on detailed revenue, margin and cash flow assumptions.

The analysts have a consensus price target of $193.71 for DaVita based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $235.0, and the most bearish reporting a price target of just $145.0.

Want to see what is baked into that $193.71 figure? The narrative leans on measured revenue growth, higher margins and a lower future earnings multiple than today.

Result: Fair Value of $193.71 (OVERVALUED)

However, DaVita’s story still hinges on sensitive assumptions, with reimbursement rates that may lag cost inflation and patient mortality trends that could keep treatment volumes under pressure.

Another View: What DaVita’s P/E Is Signalling

While the most followed DaVita narrative points to a fair value of $193.71 and an overvalued stock on that basis, the current P/E of 18.1x looks cheaper than the US Healthcare industry at 23.1x, the peer average at 37.6x, and an estimated fair ratio of 24.6x. This raises the question of whether the market is pricing in more risk than these comparables imply.

For a closer look at how this ratio based view stacks up against the broader valuation work and where the gaps might sit, it is worth reviewing the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mix of optimism and caution around DaVita resonates with you, this may be a useful moment to review the facts and refine your own thesis using the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond DaVita?

If DaVita has sharpened your focus on where to put fresh capital to work, it makes sense to line up a few more high conviction ideas before the next move.

• Seize potential mispricings by scanning 44 high quality undervalued stocks to find candidates that combine stronger fundamentals with prices that may not fully reflect their underlying strength yet.
• Build a steadier income stream by reviewing 7 dividend fortresses to identify opportunities that pair higher yields with robust underlying businesses.
• Protect your downside first by checking 70 resilient stocks with low risk scores and focusing on ideas that score well on resilience before chasing the next headline story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.